Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeImmune checkpoint blockade has revolutionized cancer therapeutics, but it doesn’t work for everyone. It may cause unacceptable immune-related adverse events, or tumors may fail to respond or develop resistance. We’re beginning to understand the biological reasons why.Immune checkpoint blockade has revolutionized cancer therapeutics, but it doesn’t work for everyone. It may cause unacceptable immune-related adverse events, or tumors may fail to respond or develop resistance. We’re beginning to understand the biological reasons why.Golnaz Morad, Beth A. Helmink, Padmanee Sharma, Jennifer A. Wargohttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2821%2901101-6%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignOctober 8, 2021

Powered by WPeMatico